ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 859.7 USD | +1.14% |
|
+3.20% | +47.17% |
| 01:00pm | US FDA advisers to review Eli Lilly Alzheimer's drug | RE |
| 12:55pm | Eli Lilly Study Shows Tirzepatide Superior to Placebo | MT |
ETFs positioned on Eli Lilly and Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.29% | 36 M€ | +2.29% | - | |
| 0.27% | 1 M€ | -.--% | - | |
| 0.24% | 13 M€ | +17.94% | - | |
| 0.23% | 18 M€ | +3.41% | - | |
| 0.22% | 104 M€ | +4.37% | - | |
| 0.21% | 8 M€ | +4.93% | - | |
| 0.21% | 31 M€ | +0.05% | - | |
| 0.21% | 20 M€ | +4.74% | - | |
| 0.20% | 252 M€ | +8.06% | ||
| 0.19% | 17 M€ | +3.59% | - | |
| 0.18% | 20 M€ | +0.79% | - | |
| 0.15% | 3 M€ | +6.48% | - | |
| 0.15% | 248 M€ | +10.66% | - | |
| 0.11% | 2 M€ | +3.16% | - | |
| 0.11% | 25 M€ | +16.49% | - | |
| 0.11% | 55 M€ | +0.86% | - | |
| 0.10% | 753 M€ | +0.87% | - | |
| 0.09% | 8 M€ | +1.08% | - | |
| 0.08% | 6 M€ | -4.26% | - | |
| 0.02% | 108 M€ | +10.56% |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
850
USD
Average target price
853.8
USD
Spread / Average Target
+0.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +47.17% | 765B | |
| -6.77% | 354B | |
| +19.42% | 331B | |
| +8.57% | 299B | |
| +18.87% | 248B | |
| -1.96% | 219B | |
| +11.11% | 216B | |
| +5.00% | 164B | |
| -2.48% | 162B | |
| +0.57% | 123B |
- Stock Market
- Equities
- LLY Stock
- Funds and ETFs Eli Lilly and Company
